• linkedin
  • Increase Font
  • Sharebar

    Clarifying ingenol labeling changes

     

    The new mention of herpes zoster in the ingenol mebutate prescribing information appears in the list of adverse reactions identified during post approval use. Dr. Rosen said the total number of instances for this event is unclear. Although there are about 20 reports of “herpes zoster”, further investigation is needed to confirm the diagnosis, as it is possible that some cases are instead herpes simplex virus (HSCV) reactivation. Then, even if the diagnosis of herpes zoster is established, it will remain unknown whether the disease was triggered by ingenol mebutate use or occurred coincidentally, considering that the majority of patients using the medication are in the ≥65 year old age group that is at highest risk for herpes zoster.

    “HSV reaction is reported in the prescribing information for several other AK topical therapies and can occur with any treatment, medical or surgical, that incites inflammation around the lips and mouth. The standard of care when using those interventions in a patient for whom there is a concern about HSV reactivation is to initiate antiviral prophylaxis. Perhaps that will also be prudent with ingenol, but first we need to learn more about the reactions occurring with its use,” he noted.

    New verbiage on hypersensitivity reactions appears in the Contraindications, Warnings and Precautions, and Adverse Reactions sections of the prescribing information. Likely what is most worrisome to dermatologists is the statement: “Anaphylaxis, as well as allergic reactions leading to hospitalization have been reported in postmarketing use with Picato gel.”

    Dr. Rosen said there have been about five such cases. However, the diagnosis of anaphylaxis has not been confirmed in all of those patients. Furthermore, he emphasized that the term “anaphylaxis” defines a spectrum of events that range from milder skin reactions to life-threatening bronchospasm.

    “It is still to be determined how severe the reactions were and if they were in fact anaphylaxis,” Dr. Rosen said.

    The other “allergic reactions” include allergic contact dermatitis (ACD). Here again, the total number reported is no more than five, and the diagnosis is questionable.
    “Local skin reactions are expected to develop after application of ingenol or other AK field therapies. They include redness, swelling, flaking, and scaling — all of which mimic the signs of ACD,” Dr. Rosen said

    The revised prescribing information also reiterates directions about avoiding transfer of medication to the periocular area and application near and around the mouth and lips. It also reinforces that the area of application should be up to one contiguous area of approximately 25 cm2. Dr. Rosen pointed out this direction for administration is consistent with the method used in the pivotal clinical trials.

    Disclosure: Dr. Rosen received an honorarium for participation in an advisory board meeting sponsored by Leo Pharma, USA.

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Latest Tweets Follow